News Releases

View all Historical Press Releases

Investor Alerts

Dec 11, 2018

Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Princeton, NJ – December 11, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Dec 5, 2018

Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology

Highlights Potential for Treating Multiple Diseases with Dusquetide and Related IDR Analogs

Princeton, NJ – December 5, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Nov 12, 2018

Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland

Princeton, NJ – November 12, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Nov 9, 2018

Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results

PRINCETON, NJ – November 9, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 15, 2018

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma

Princeton, NJ – October 15, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...

Show per page